Quantcast
Last updated on April 19, 2014 at 17:21 EDT

Latest TWi Biotechnology Inc. Stories

2013-09-10 08:31:20

TAIPEI, Sept. 10, 2013 /PRNewswire/ -- TWi Biotechnology, Inc., today announced that it has received an official notification of patent allowance for AC-201, TWi Biotechnology's lead drug candidate, from the United States Patent & Trademark Office. The granted patent, US patent number 8,536,152, covers AC-201's use as a combination therapy with other existing blood glucose lowering therapy agents to treat Type II diabetes. The patent is part of TWi Biotechnology's broad...

2013-06-18 00:20:34

TAIPEI, Taiwan, June 17, 2013 /PRNewswire/ -- TWi Biotechnology, Inc. today announced that it has completed the patient enrollment in a phase II trial of AC-201 for Gout Flare Prophylaxis (GFP) during urate-lowering therapy (ULT). This randomized, double-blind, placebo-controlled Phase II study is conducted in 8 major medical centers in Taiwan. This study includes patients with acute arthritis of primary gout and elevated serum uric acid. A total of 82 patients were randomized at...

2013-05-30 08:29:48

TAIPEI, Taiwan, May 30, 2013 /PRNewswire/ -- TWi Biotechnology, Inc. today announced that it has received an official notification of patent allowance for AC-201, TWi Biotechnology's lead drug candidate, from China State Intellectual Property Office of Patent. The granted patent claims cover AC-201's composition of matter and uses to treat various inflammatory, autoimmune diseases such as Type I/II diabetes, osteoarthritis and the complications of these diseases. The patent is part of TWi...

2012-08-06 02:25:26

TAIPEI, Taiwan, Aug. 6, 2012 /PRNewswire-Asia/ -- TWi Pharmaceuticals, Inc., a specialty pharmaceutical company based in Taiwan, today announced its fully owned subsidiary, TWi Biotechnology, Inc. has completed a multinational phase II dose-ranging study of AC-201, an orally available IL-1 Beta modulator, in 259 patients with type II diabetes uncontrolled on up to three oral medications. In the intent-to-treat population, AC-201 showed placebo-corrected reductions in HbA1c of 0.20%,...

2011-09-07 04:00:00

TAIPEI, Taiwan, Sept. 7, 2011 /PRNewswire-Asia/ -- TWi Biotechnology, Inc. announces the successful patient recruitment for the multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb clinical trial of AC-201 for the treatment of Type II Diabetes. A combined 240 patients from 13 US sites plus 8 Taiwan sites have been enrolled to the trial. With six-month treatment and one-month follow-up, completion of the trial data analysis is expected in the...

2011-06-14 04:00:00

TAIPEI, Taiwan, June 14, 2011 /PRNewswire-Asia/ -- TWi Biotechnology Inc. announced today that the company has enrolled over 50% of the total 240 patients for the Phase IIb clinical trial of AC-201 for the treatment of Type II Diabetes. The randomized, double-blind, placebo-controlled, dose-ranging, multi-center study is primarily designed to evaluate the glycated hemoglglobin A1c (HbA1c) lowering effects of AC-201 in patients with Type II Diabetes Mellitus. Meanwhile, the cardiovascular...